PR Newswire
NEW YORK , July 14, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Bausch Health Companies Inc. (NYSE: BHC)
To be contacted by a member of our team, fill out the form:
https://claimyourloss.com/securities/bausch-health-class-action-loss-submission-form/?id=42097&from=4
Further details on the investigation: The investigation focuses on whether Bausch Health issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning its 2022 earnings and guidance and its patent dispute over Xifaxan. On May 10, 2022 , Bausch Health announced its first-quarter 2022 results, prompting the stock price to fall $3.50 per share. Analysts attributed the decline to concerns around the Company's spin-off of Bausch + Lomb Corporation, high debt levels, and anticipation over the Xifaxan patent decision. On July 28, 2022 , the Company issued an update on the Xifaxan patent dispute case between Bausch Health and Norwich . In response to this news, market analysts downgraded Bausch Health and its stock price fell an additional $3.58 per share, representing a decline of more than 50% from its trading price just two months earlier.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud . Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
SOURCE Jakubowitz Law